• Home
  • A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.

A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.

Author List
Kieran MW, Chi S, Goldman S, Onar-Thomas A, Poussaint TY, Vajapeyam S, Fahey F, Wu S, Turner DC, Stewart CF, Moses M, Packer RJ, Jakacki R, Banerjee A, Boyett JM, Fouladi M, Kun L
Publication
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
Publication ID (Profile URL)
https://researcherprofiles.org/profile/1192935
Publication Year
2015
PubMed ID
26188774
Publication Title
Kieran MW, Chi S, Goldman S, Onar-Thomas A, Poussaint TY, Vajapeyam S, Fahey F, Wu S, Turner DC, Stewart CF, Moses M, Packer RJ, Jakacki R, Banerjee A, Boyett JM, Fouladi M, Kun L. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. Childs Nerv Syst. 2015 Sep; 31(9):1433-45.